繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-810 (SAFETYNADOL)

SNP-810 (SAFETYNADOL)

Indication
Hepatotoxicity-free Acetaminophen (Analgesic and antipyretic)
Product Advantages
1. Hepatotoxicity-free
2. To address the important and urgent unmet medical needs
3. A patented formulation with great safety margin
Status
Phase I low-dose, high-dose completed (Pivotal trial applying for USFDA NDA)
Competitive Edge
1. Currently, no hepatotoxicity-free acetaminophen on the market
2. Great impact on the market share of pain controllers, especially to NSAIDS, Cox2 inhibitors and opioids
3. Reduction of lawsuit and compensation
Potential Market
Acetaminophen sales are 1.3 billion USD a year (US only)

Mechanism of Action of SNP-810 and NAC


模拟人生4 俱乐部赚钱 湖北快三 五分彩后一稳赚公式 贵州茅台股票 北京pk10定位胆怎么玩的 免费两码中特永久公开王中王 云南时时彩开奖官方 好股票推荐 近期 股票配资渠道 浙江6+1走势图带连线专业版 贵州十一选五走势分布图